UMN Pharma Inc. today announced initiation of phase I/II clinical
trials in human subjects with UMN-0501, UMN's pandemic influenza
vaccine. In Japan, this is the "first-in-man" clinical study of a
pandemic influenza vaccine manufactured by cell-culture. The purpose of
this clinical study is to assess safety and efficacy in 125 healthy
adults aged 20-40. Study results will be obtained by the end of the
year.
 News
release PDF file. (39K)
 |
In order to view this file, you will need to have the following plug-in installed. |
|
